Key points are not available for this paper at this time.
Shifting to a nonprofit-driven model for development of antibiotics could encourage discovery and development of truly needed drugs that improve patient outcomes and permit more effective control over the postapproval use of antibiotics to prolong their effectiveness.
Nielsen et al. (Wed,) studied this question.